In Friday’s Wall Street session, Roivant Sciences Ltd (NASDAQ:ROIV) shares traded at $9.46, down -5.49% from the previous session.
ROIV stock price is now -10.98% away from the 50-day moving average and -16.26% away from the 200-day moving average. The market capitalization of the company currently stands at $6.75B.
With the price target of $17, Wolfe Research recently initiated with Outperform rating for Roivant Sciences Ltd (NASDAQ: ROIV). On January 05, 2024, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $20, while ‘Deutsche Bank’ rates the stock as ‘Buy’
In other news, Venker Eric, President & COO sold 434,478 shares of the company’s stock on Mar 24 ’25. The stock was sold for $4,701,052 at an average price of $10.82. Upon completion of the transaction, the President & COO now directly owns 1,127,290 shares in the company, valued at $10.66 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 20 ’25, President & COO Venker Eric sold 315,522 shares of the business’s stock. A total of $3,489,673 was realized by selling the stock at an average price of $11.06. This leaves the insider owning 959,457 shares of the company worth $9.08 million. A total of 38.52% of the company’s stock is owned by insiders.
During the past 12 months, Roivant Sciences Ltd has had a low of $9.76 and a high of $13.06. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 37.91, and a quick ratio of 37.91. The fifty day moving average price for ROIV is $10.6272 and a two-hundred day moving average price translates $11.29665 for the stock.
The latest earnings results from Roivant Sciences Ltd (NASDAQ: ROIV) was released for 2024-12-31. The net profit margin was -119.54% and return on equity was -7.10% for ROIV. The company reported revenue of $9.02 million for the quarter, compared to $15.56 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -42.05 percent.
